United States Financial Markets News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Search entities
Discover all 32,649 supported financial entities for United States financial markets here.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 2481,
"returned": 10,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "7ae7101e-310d-4f9e-85e8-670b10807330",
"title": "Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025 | HRMY Stock News",
"description": "Harmony Biosciences (HRMY) to announce Q2 2025 financial results on August 5, 2025. An investor call and webcast are scheduled for 8:30 a.m. ET on the s",
"keywords": "GuruFocus, Article, News, GuruFocus News, HRMY",
"snippet": "Harmony Biosciences (HRMY, Financial) to announce Q2 2025 financial results on August 5, 2025.\n\nAn investor call and webcast are scheduled for 8:30 a.m. ET on t...",
"url": "https://www.gurufocus.com/news/2993278/harmony-biosciences-to-report-second-quarter-2025-financial-results-on-august-5-2025-hrmy-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C0000BXS4.png?20",
"language": "en",
"published_at": "2025-07-22T13:21:44.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "HRMY",
"name": "Harmony Biosciences Holdings, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 52.584633,
"sentiment_score": 0.6705,
"highlights": [
{
"highlight": "<em>Harmony</em> <em>Biosciences</em> <e[+209 characters]",
"sentiment": 0.6705,
"highlighted_in": "main_text"
}
]
}
],
"similar": [
{
"uuid": "1f6c5d90-1281-4375-87bc-06c7c2833d8d",
"title": "908 Devices to Report Second Quarter 2025 Financial Results on August 5, 2025 | MASS Stock News",
"description": "908 Devices Inc. (MASS) will release its Q2 2025 financial results on August 5, 2025. A live webcast of the earnings call will be held at 8:30 a.m. East",
"keywords": "GuruFocus, Article, News, GuruFocus News, MASS",
"snippet": "908 Devices Inc. (MASS, Financial) will release its Q2 2025 financial results on August 5, 2025.\n\nA live webcast of the earnings call will be held at 8:30 a.m. ...",
"url": "https://www.gurufocus.com/news/2992702/908-devices-to-report-second-quarter-2025-financial-results-on-august-5-2025-mass-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C0000C0VA.png?20",
"language": "en",
"published_at": "2025-07-22T12:16:08.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "MASS",
"name": "908 Devices Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 81.48526,
"sentiment_score": 0.375975,
"highlights": [
{
"highlight": "<em>908</em> <em>Devices</em> <em>Inc</e[+284 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Investors and interested parties can acc[+133 characters]",
"sentiment": 0.6597,
"highlighted_in": "main_text"
},
{
"highlight": "The recorded webcast will be available f[+331 characters]",
"sentiment": 0.8442,
"highlighted_in": "main_text"
},
{
"highlight": "<em>908</em> <em>Devices</em> to Report Second Quarter 2025 Financial Results on August 5, 2025 | MASS Stock News",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "126ae2f7-c48b-4ae1-bf26-91c42327b3d9",
"title": "Evolus to Report Second Quarter Financial Results on August 5, 2025 | EOLS Stock News",
"description": "Evolus, Inc. (EOLS), a performance beauty company, will release its Q2 2025 financial results on August 5, after market close. A conference call and liv",
"keywords": "GuruFocus, Article, News, GuruFocus News, EOLS",
"snippet": "Evolus, Inc. (EOLS, Financial), a performance beauty company, will release its Q2 2025 financial results on August 5, after market close.\n\nA conference call and...",
"url": "https://www.gurufocus.com/news/2993274/evolus-to-report-second-quarter-financial-results-on-august-5-2025-eols-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C0000BDYP.png?20",
"language": "en",
"published_at": "2025-07-22T13:21:33.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "EOLS",
"name": "Evolus, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 60.74202,
"sentiment_score": 0.5507,
"highlights": [
{
"highlight": "<em>Evolus</em>, <em>Inc</em>. (EOLS, Fi[+322 characters]",
"sentiment": 0.5859,
"highlighted_in": "main_text"
},
{
"highlight": "Following the results release, <em>Evolu[+313 characters]",
"sentiment": 0.765,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Evolus</em> continues to position it[+298 characters]",
"sentiment": 0.8519,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Evolus</em> to Report Second Quarter Financial Results on August 5, 2025 | EOLS Stock News",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "a881b3ed-8a2c-43d2-848f-5df6946c967d",
"title": "iQIYI to Report Second Quarter 2025 Financial Results on August 20, 2025 | IQ Stock News",
"description": "iQIYI (IQ) to announce Q2 2025 financial results on August 20, 2025, before U.S. market opens. The earnings conference call is set for 7:00 AM ET on the",
"keywords": "GuruFocus, Article, News, GuruFocus News, IQ",
"snippet": "iQIYI (IQ, Financial) to announce Q2 2025 financial results on August 20, 2025, before U.S. market opens.\n\nThe earnings conference call is set for 7:00 AM ET on...",
"url": "https://www.gurufocus.com/news/2992324/iqiyi-to-report-second-quarter-2025-financial-results-on-august-20-2025-iq-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C0000BEL0.png?20",
"language": "en",
"published_at": "2025-07-22T10:15:43.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "IQ",
"name": "iQIYI, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Communication Services",
"match_score": 49.695877,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>iQIYI</em> (IQ, Financial) to announ[+281 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>iQIYI</em> to Report Second Quarter 2025 Financial Results on August 20, 2025 | IQ Stock News",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "64e78f55-7f06-4d55-b54d-c1f3cdd039af",
"title": "Kingstone Reinstates Quarterly Cash Dividend Reflecting Strong Financial Position | KINS Stock News",
"description": "Kingstone Companies (KINS) reinstates a quarterly dividend of $0.05 per share after a nearly three-year suspension. The decision reflects strong financi",
"keywords": "GuruFocus, Article, News, GuruFocus News, KINS",
"snippet": "Kingstone Companies (KINS, Financial) reinstates a quarterly dividend of $0.05 per share after a nearly three-year suspension.\n\nThe decision reflects strong fin...",
"url": "https://www.gurufocus.com/news/2993272/kingstone-reinstates-quarterly-cash-dividend-reflecting-strong-financial-position-kins-stock-news",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-07-22T13:21:26.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "KINS",
"name": "Kingstone Companies, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 48.07062,
"sentiment_score": 0.17265,
"highlights": [
{
"highlight": "<em>Kingstone</em> <em>Companies</em> (K[+301 characters]",
"sentiment": 0.872,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Kingstone</em> <em>Companies</em>, <[+180 characters]",
"sentiment": -0.5267,
"highlighted_in": "main_text"
}
]
}
],
"similar": [
{
"uuid": "b5c47b95-10cc-4f1a-8db6-b596f05a2066",
"title": "BNP Paribas Exane Elevates Cooper Companies (COO) Rating to Outperform | COO Stock News",
"description": "BNP Paribas Exane has upgraded its rating for Cooper Companies (COO) from Neutral to Outperform. The investment firm also set a price target of $92 for the stoc",
"keywords": "GuruFocus, Article, News, GuruFocus News, COO",
"snippet": "BNP Paribas Exane has upgraded its rating for Cooper Companies (COO, Financial) from Neutral to Outperform. The investment firm also set a price target of $92 f...",
"url": "https://www.gurufocus.com/news/2992818/bnp-paribas-exane-elevates-cooper-companies-coo-rating-to-outperform-coo-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C00000AQD.png?20",
"language": "en",
"published_at": "2025-07-22T12:30:28.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "COO",
"name": "The Cooper Companies, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 44.411545,
"sentiment_score": 0.27998,
"highlights": [
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+310 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+307 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+268 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+331 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>The</em> <em>Cooper[+230 characters]",
"sentiment": 0.8555,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "1c3345d4-b596-4e16-a7f2-2e9596cbc95a",
"title": "Fusion Fuel's BrightHy Solutions Announces Non-Binding Term Sheet for Strategic Partnership with €30 Million Commitment for Hydrogen Infrastructure Investments | HTOO Stock News",
"description": "Fusion Fuel Green's subsidiary, BrightHy Solutions, signs a non-binding Term Sheet for a €30 million hydrogen infrastructure partnership. The agreemen",
"keywords": "GuruFocus, Article, News, GuruFocus News, HTOO",
"snippet": "Fusion Fuel Green's subsidiary, BrightHy Solutions, signs a non-binding Term Sheet for a €30 million hydrogen infrastructure partnership.\n\nThe agreement invol...",
"url": "https://www.gurufocus.com/news/2993270/fusion-fuels-brighthy-solutions-announces-nonbinding-term-sheet-for-strategic-partnership-with-30-million-commitment-for-hydrogen-infrastructure-investments-htoo-stock-news",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-07-22T13:21:11.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "HTOO",
"name": "Fusion Fuel Green PLC",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Utilities",
"match_score": 72.10359,
"sentiment_score": 0.7096,
"highlights": [
{
"highlight": "<em>Fusion</em> <em>Fuel</em> <em>Green<[+329 characters]",
"sentiment": 0.7096,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "HTOOW",
"name": "Fusion Fuel Green PLC",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "N/A",
"match_score": 51.80787,
"sentiment_score": 0.7096,
"highlights": [
{
"highlight": "<em>Fusion</em> <em>Fuel</em> <em>Green<[+311 characters]",
"sentiment": 0.7096,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "f55c4204-a289-436e-9f37-e65890846124",
"title": "aTyr Pharma (ATYR) Concludes Patient Visits in Phase 3 EFZO-FIT Study | ATYR Stock News",
"description": "aTyr Pharma (ATYR) announced the completion of patient visits in its Phase 3 EFZO-FIT study for its primary therapeutic candidate, efzofitimod. This study focus",
"keywords": "GuruFocus, Article, News, GuruFocus News, ATYR",
"snippet": "aTyr Pharma (ATYR, Financial) announced the completion of patient visits in its Phase 3 EFZO-FIT study for its primary therapeutic candidate, efzofitimod. This ...",
"url": "https://www.gurufocus.com/news/2993266/atyr-pharma-atyr-concludes-patient-visits-in-phase-3-efzofit-study-atyr-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C0000AW8F.png?20",
"language": "en",
"published_at": "2025-07-22T13:20:57.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "LIFE",
"name": "aTyr Pharma, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 104.36769,
"sentiment_score": -0.017725,
"highlights": [
{
"highlight": "<em>aTyr</em> <em>Pharma</em> (ATYR, Fin[+244 characters]",
"sentiment": 0.2023,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+291 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+272 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>aTyr</em> <em>Pharma</em> (ATYR) Concludes Patient Visits in Phase 3 EFZO-FIT Study | ATYR Stock News",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "b53a7f6c-f6a1-49c3-8ae9-da72b45e73e9",
"title": "aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis | ATYR Stock News",
"description": "aTyr Pharma (ATYR) concludes Phase 3 EFZO-FITâ„¢ study for efzofitimod with last patient visit.The study involved 268 pulmonary sarcoidosis patients across the",
"keywords": "GuruFocus, Article, News, GuruFocus News, ATYR",
"snippet": "aTyr Pharma (ATYR, Financial) concludes Phase 3 EFZO-FIT™ study for efzofitimod with last patient visit.\n\nThe study involved 268 pulmonary sarcoidosis patient...",
"url": "https://www.gurufocus.com/news/2993251/atyr-pharma-announces-last-patient-visit-in-phase-3-efzofit-study-of-efzofitimod-in-patients-with-pulmonary-sarcoidosis-atyr-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C0000AW8F.png?20",
"language": "en",
"published_at": "2025-07-22T13:20:11.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "LIFE",
"name": "aTyr Pharma, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 73.60033,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>aTyr</em> <em>Pharma</em> (ATYR, Fin[+316 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>aTyr</em> <em>Pharma</em> Announces Last Patient Visit in Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis | ATYR Stock News",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "223a2279-b732-4dc4-b5f0-ef32faff4b3e",
"title": "Royalty Pharma (RPRX) Price Target Increased by Citi | RPRX Stock News",
"description": "Citi has adjusted its price target for Royalty Pharma (RPRX), raising it from $40 to $42 while maintaining a Buy rating on the shares. This adjustment is part o",
"keywords": "GuruFocus, Article, News, GuruFocus News, RPRX",
"snippet": "Citi has adjusted its price target for Royalty Pharma (RPRX, Financial), raising it from $40 to $42 while maintaining a Buy rating on the shares. This adjustmen...",
"url": "https://www.gurufocus.com/news/2992469/royalty-pharma-rprx-price-target-increased-by-citi-rprx-stock-news",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-07-22T11:32:50.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "RPRX",
"name": "Royalty Pharma plc",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 89.59949,
"sentiment_score": 0.337089,
"highlights": [
{
"highlight": "Citi has adjusted its price target for <[+217 characters]",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+294 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+278 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+253 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+240 characters]",
"sentiment": 0.7783,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>Royalty</em> <em>Ph[+273 characters]",
"sentiment": 0.9231,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Royalty</em> <em>Pharma</em> <em>PLC[+249 characters]",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Royalty</em> <em>Pharma</em> <em>PLC[+166 characters]",
"sentiment": -0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Royalty</em> <em>Pharma</em> (RPRX) Price Target Increased by Citi | RPRX Stock News",
"sentiment": 0.2732,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "3e30f6db-4324-4abf-bc4c-903db6281dcb",
"title": "Earnings To Watch: Popular Inc (BPOP) Reports Q2 2025 Result",
"description": "Popular Inc (BPOP) is set to release its Q2 2025 earnings on Jul 23, 2025. The consensus estimate for Q2 2025 revenue is $636.21 million, and the earnings are e",
"keywords": "GuruFocus, Article, News, GuruFocus News, BPOP",
"snippet": "Popular Inc (BPOP, Financial) is set to release its Q2 2025 earnings on Jul 23, 2025. The consensus estimate for Q2 2025 revenue is $636.21 million, and the ear...",
"url": "https://www.gurufocus.com/news/2993260/earnings-to-watch-popular-inc-bpop-reports-q2-2025-result",
"image_url": "https://static.gurufocus.com/logos/0C00000CAP.png?14",
"language": "en",
"published_at": "2025-07-22T13:20:39.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "BPOPO",
"name": "Popular, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 65.7225,
"sentiment_score": 0.137188,
"highlights": [
{
"highlight": "<em>Popular</em> <em>Inc</em> (BPOP, Fin[+302 characters]",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Popular</em> <em>Inc</em> (BPOP, Fin[+230 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Popular</em> <em>Inc</em> (BPOP, Fin[+211 characters]",
"sentiment": -0.296,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Popular</em> Inc's (BPOP) actual ear[+194 characters]",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Popular</em> <em>Inc</em> (BPOP, Fin[+311 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+155 characters]",
"sentiment": 0.1027,
"highlighted_in": "main_text"
},
{
"highlight": "Based on the consensus recommendation fr[+235 characters]",
"sentiment": 0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "Earnings To Watch: <em>Popular</em> <em>Inc</em> (BPOP) Reports Q2 2025 Result",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "e144fac0-7175-4659-8273-98314f239cb0",
"title": "Earnings To Watch: Graco Inc (GGG) Reports Q2 2025 Result",
"description": "Graco Inc (GGG) is set to release its Q2 2025 earnings on Jul 23, 2025. The consensus estimate for Q2 2025 revenue is $589.49 million, and the earnings are expe",
"keywords": "GuruFocus, Article, News, GuruFocus News, GGG",
"snippet": "Graco Inc (GGG, Financial) is set to release its Q2 2025 earnings on Jul 23, 2025. The consensus estimate for Q2 2025 revenue is $589.49 million, and the earnin...",
"url": "https://www.gurufocus.com/news/2993224/earnings-to-watch-graco-inc-ggg-reports-q2-2025-result",
"image_url": "https://static.gurufocus.com/logos/0C000007Y0.png?14",
"language": "en",
"published_at": "2025-07-22T13:18:35.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "GGG",
"name": "Graco Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Industrials",
"match_score": 93.615395,
"sentiment_score": 0.293438,
"highlights": [
{
"highlight": "<em>Graco</em> <em>Inc</em> (GGG, Financ[+296 characters]",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Graco</em> <em>Inc</em> (GGG, Financ[+233 characters]",
"sentiment": 0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "Earnings estimates for <em>Graco</em> <e[+162 characters]",
"sentiment": 0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Graco</em> <em>Inc</em> (GGG, Financ[+332 characters]",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "After releasing the results, <em>Graco</[+316 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+149 characters]",
"sentiment": 0.1027,
"highlighted_in": "main_text"
},
{
"highlight": "Based on the consensus recommendation fr[+233 characters]",
"sentiment": 0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "Earnings To Watch: <em>Graco</em> <em>Inc</em> (GGG) Reports Q2 2025 Result",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "d3dad0b3-3d4f-49a7-a506-a89bf0cbf364",
"title": "What To Expect From Mr. Cooper Group Inc (COOP) Q2 2025 Earnings",
"description": "Mr. Cooper Group Inc (COOP) is set to release its Q2 2025 earnings on Jul 23, 2025. The consensus estimate for Q2 2025 revenue is $671.67 million, and the earni",
"keywords": "GuruFocus, Article, News, GuruFocus News, COOP",
"snippet": "Mr. Cooper Group Inc (COOP, Financial) is set to release its Q2 2025 earnings on Jul 23, 2025. The consensus estimate for Q2 2025 revenue is $671.67 million, an...",
"url": "https://www.gurufocus.com/news/2993252/what-to-expect-from-mr-cooper-group-inc-coop-q2-2025-earnings",
"image_url": "https://static.gurufocus.com/logos/0C000009LB.png?14",
"language": "en",
"published_at": "2025-07-22T13:20:14.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "COOP",
"name": "Mr. Cooper Group Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 137.86624,
"sentiment_score": 0.14465,
"highlights": [
{
"highlight": "<em>Mr</em>. <em>Cooper</em> <em>Group</[+330 characters]",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Mr</em>. <em>Cooper</em> <em>Group</[+363 characters]",
"sentiment": 0.4939,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Mr</em>. <em>Cooper</em> <em>Group</[+270 characters]",
"sentiment": -0.296,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Cooper</em> Group Inc's (COOP) actua[+246 characters]",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Cooper</em> <em>Group</em> <em>Inc</[+355 characters]",
"sentiment": -0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+258 characters]",
"sentiment": 0.1027,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Cooper</em> Group Inc's (COOP, Finan[+288 characters]",
"sentiment": 0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "What To Expect From <em>Mr</em>. <em>Cooper</em> <em>Group</em> <em>Inc</em> (COOP) Q2 2025 Earnings",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "ab28562b-2318-498e-b7ac-6a32ee5168d4",
"title": "LifeVantage Announces Expanded Human Clinical Study for MindBody GLP-1 System™; Findings Increase Average in Natural GLP-1 Production to Over 200%‡‡ | LFVN Stock News",
"description": "LifeVantage (LFVN) reports over 200% increase in natural GLP-1 production from clinical trials. Average weight loss reported at 11 pounds over 12 weeks,",
"keywords": "GuruFocus, Article, News, GuruFocus News, LFVN",
"snippet": "LifeVantage (LFVN, Financial) reports over 200% increase in natural GLP-1 production from clinical trials.\n\nAverage weight loss reported at 11 pounds over 12 we...",
"url": "https://www.gurufocus.com/news/2993250/lifevantage-announces-expanded-human-clinical-study-for-mindbody-glp1-system-findings-increase-average-in-natural-glp1-production-to-over-200-lfvn-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C0000083N.png?20",
"language": "en",
"published_at": "2025-07-22T13:20:05.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "LFVN",
"name": "LifeVantage Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Defensive",
"match_score": 49.167576,
"sentiment_score": 0.743533,
"highlights": [
{
"highlight": "<em>LifeVantage</em> (LFVN, Financial) r[+284 characters]",
"sentiment": 0.8271,
"highlighted_in": "main_text"
},
{
"highlight": "<em>LifeVantage</em> <em>Corporation</em[+301 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "<em>LifeVantage</em> Announces Expanded Human Clinical Study for MindBody GLP-1 System™; Findings Increase Average in Natural GLP-1 Production to Over 200%‡‡ | LFVN Stock News",
"sentiment": 0.5859,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "803c70bd-0d99-496c-a50e-b10f2be04e7b",
"title": "LifeVantage Announces Expanded Human Clinical Study for MindBody GLP-1 System™; Findings Increase Average in Natural GLP-1 Production to Over 200%‡‡",
"description": "Expanded U.S.-clinical research study shows strong results including increased fat loss, improved cravings control, and healthier body composition*”¡\n\nSALT LA",
"keywords": "GuruFocus, Article, News, Marketwired, LFVN",
"snippet": "SALT LAKE CITY, July 22, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation ( LFVN), a leading health and wellness company with products designed to activate opti...",
"url": "https://www.gurufocus.com/news/2993054/lifevantage-announces-expanded-human-clinical-study-for-mindbody-glp1-system-findings-increase-average-in-natural-glp1-production-to-over-200",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-07-22T13:00:06.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "LFVN",
"name": "LifeVantage Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Defensive",
"match_score": 53.76507,
"sentiment_score": 0.5466,
"highlights": [
{
"highlight": "SALT LAKE CITY, July 22, 2025 (GLOBE NEW[+337 characters]",
"sentiment": 0.7624,
"highlighted_in": "main_text"
},
{
"highlight": "result further reinforces the effectiven[+340 characters]",
"sentiment": 0.93,
"highlighted_in": "main_text"
},
{
"highlight": "their relationship with food:\n\n95% repor[+346 characters]",
"sentiment": 0.5994,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>LifeVantage</em> <em>Corporati[+321 characters]",
"sentiment": 0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "<em>LifeVantage</em> was founded in 2003[+181 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>LifeVantage</em> Announces Expanded Human Clinical Study for MindBody GLP-1 System™; Findings Increase Average in Natural GLP-1 Production to Over 200%‡‡",
"sentiment": 0.5859,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "d47e748c-10cf-491e-9a6b-a7c9386c6615",
"title": "IQVIA Reports Second-Quarter 2025 Results | IQV Stock News",
"description": "IQVIA (IQV) reported a 5.3% increase in Q2 2025 revenue, totaling $4,017 million. Adjusted Diluted Earnings per Share reached $2.81, with an Adjusted EBITDA",
"keywords": "GuruFocus, Article, News, GuruFocus News, IQV",
"snippet": "IQVIA (IQV, Financial) reported a 5.3% increase in Q2 2025 revenue, totaling $4,017 million.\n\nAdjusted Diluted Earnings per Share reached $2.81, with an Adjuste...",
"url": "https://www.gurufocus.com/news/2992797/iqvia-reports-secondquarter-2025-results-iqv-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C00009UD5.png?20",
"language": "en",
"published_at": "2025-07-22T12:21:46.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "0JDM.L",
"name": "IQVIA Holdings Inc.",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 39.824814,
"sentiment_score": 0.4767,
"highlights": [
{
"highlight": "<em>IQVIA</em> <em>Holdings</em> <em>Inc[+270 characters]",
"sentiment": 0.4767,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "I1QV34.SA",
"name": "IQVIA Holdings Inc.",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 39.82161,
"sentiment_score": 0.4767,
"highlights": [
{
"highlight": "<em>IQVIA</em> <em>Holdings</em> <em>Inc[+270 characters]",
"sentiment": 0.4767,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "IQV",
"name": "IQVIA Holdings Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 39.80053,
"sentiment_score": 0.4767,
"highlights": [
{
"highlight": "<em>IQVIA</em> <em>Holdings</em> <em>Inc[+270 characters]",
"sentiment": 0.4767,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "02e389c3-906b-46b9-9e83-4aeb222ee04e",
"title": "Pentair (PNR) Reports Q2 Revenue Below Expectations | PNR Stock News",
"description": "Pentair (PNR) reported its second-quarter revenue, totaling $1.1 billion, which was slightly below the consensus estimate of $1.12 billion. Despite the shortfal",
"keywords": "GuruFocus, Article, News, GuruFocus News, PNR",
"snippet": "Pentair (PNR, Financial) reported its second-quarter revenue, totaling $1.1 billion, which was slightly below the consensus estimate of $1.12 billion. Despite t...",
"url": "https://www.gurufocus.com/news/2992742/pentair-pnr-reports-q2-revenue-below-expectations-pnr-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C00000C6B.png?20",
"language": "en",
"published_at": "2025-07-22T12:18:34.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "0Y5X.L",
"name": "Pentair plc",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 68.5766,
"sentiment_score": 0.60665,
"highlights": [
{
"highlight": "<em>Pentair</em> (PNR, Financial) report[+264 characters]",
"sentiment": 0.8225,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Pentair</em> is committed to investi[+325 characters]",
"sentiment": 0.8834,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+332 characters]",
"sentiment": 0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+238 characters]",
"sentiment": 0.7579,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+280 characters]",
"sentiment": 0.4939,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>Pentair</em> <em>PL[+238 characters]",
"sentiment": 0.891,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Pentair</em> <em>PLC</em> (PNR) main[+280 characters]",
"sentiment": 0.4939,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Pentair</em> (PNR) Reports Q2 Revenue Below Expectations | PNR Stock News",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "PNR",
"name": "Pentair plc",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Industrials",
"match_score": 68.3516,
"sentiment_score": 0.60665,
"highlights": [
{
"highlight": "<em>Pentair</em> (PNR, Financial) report[+264 characters]",
"sentiment": 0.8225,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Pentair</em> is committed to investi[+325 characters]",
"sentiment": 0.8834,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+332 characters]",
"sentiment": 0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+238 characters]",
"sentiment": 0.7579,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+280 characters]",
"sentiment": 0.4939,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>Pentair</em> <em>PL[+238 characters]",
"sentiment": 0.891,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Pentair</em> <em>PLC</em> (PNR) main[+280 characters]",
"sentiment": 0.4939,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Pentair</em> (PNR) Reports Q2 Revenue Below Expectations | PNR Stock News",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "e81ba6ce-2cf4-4ac8-9f66-fdae0b853bb5",
"title": "Sutro Biopharma Announces Research Collaboration with the FDA to Advance Regulatory Standards for Antibody Drug Conjugates | STRO Stock News",
"description": "Sutro Biopharma (STRO) collaborates with the FDA to enhance regulatory standards for Antibody Drug Conjugates (ADCs). The partnership will use Sutro's p",
"keywords": "GuruFocus, Article, News, GuruFocus News, STRO",
"snippet": "Sutro Biopharma (STRO, Financial) collaborates with the FDA to enhance regulatory standards for Antibody Drug Conjugates (ADCs).\n\nThe partnership will use Sutro...",
"url": "https://www.gurufocus.com/news/2993248/sutro-biopharma-announces-research-collaboration-with-the-fda-to-advance-regulatory-standards-for-antibody-drug-conjugates-stro-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C0000BIA6.png?20",
"language": "en",
"published_at": "2025-07-22T13:20:00.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "STRO",
"name": "Sutro Biopharma, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 106.66742,
"sentiment_score": 0.1468,
"highlights": [
{
"highlight": "<em>Sutro</em> <em>Biopharma</em> (STRO,[+237 characters]",
"sentiment": 0.4404,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Sutro</em> <em>Biopharma</em>, <em>I[+233 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Sutro</em> <em>Biopharma</em> Announces Research Collaboration with the FDA to Advance Regulatory Standards for Antibody Drug Conjugates | STRO Stock News",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "501410a0-6502-4088-8eb6-85ccef6796c1",
"title": "Sutro Biopharma Announces Research Collaboration with the FDA to Advance Regulatory Standards for Antibody Drug Conjugates",
"description": "SOUTH SAN FRANCISCO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it has entered into a collaboration with the U.S. Food and Drug Administration (FDA) to develop reference materials to improve regulatory standards and enhance analytical methods for ADC drug development. The collaboration will leverage Sutro’s cell-free XpressCF® technology to precisely engineer ADCs with predefined attributes, as well as FDA’s cutting-edge analytical capabilities to fully characterize these materials.",
"keywords": "Sutro, Biopharma, Announces, Research, Collaboration, with, the, FDA, to, Advance, Regulatory, Standards, for, Antibody, Drug, Conjugates",
"snippet": "SOUTH SAN FRANCISCO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-...",
"url": "https://www.manilatimes.net/2025/07/22/tmt-newswire/globenewswire/sutro-biopharma-announces-research-collaboration-with-the-fda-to-advance-regulatory-standards-for-antibody-drug-conjugates/2153792",
"image_url": "https://www.manilatimes.net/manilatimes/uploads/images/2025/07/22/686539.png",
"language": "en",
"published_at": "2025-07-22T12:07:58.000000Z",
"source": "manilatimes.net",
"relevance_score": null,
"entities": [
{
"symbol": "STRO",
"name": "Sutro Biopharma, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 102.93623,
"sentiment_score": 0.181725,
"highlights": [
{
"highlight": "., July 22, 2025 (GLOBE NEWSWIRE) -- <em[+268 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Sutro</em> <em>Biopharma</em>\n[+355 characters]",
"sentiment": 0.7269,
"highlighted_in": "main_text"
},
{
"highlight": "Advertisement\n\nInvestor Contact\n\nEmily W[+176 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Sutro</em> <em>Biopharma</em> Announces Research Collaboration with the FDA to Advance Regulatory Standards for Antibody Drug Conjugates",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "dcd5b216-aece-4130-9af1-78ab85c69c5b",
"title": "DMC Global Schedules Second Quarter Earnings Release and Conference Call | BOOM Stock News",
"description": "DMC Global Inc. (BOOM) to release Q2 2025 earnings on August 5, 2025. Conference call scheduled for 5:00 PM Eastern Time. Webcast replay available fo",
"keywords": "GuruFocus, Article, News, GuruFocus News, BOOM",
"snippet": "DMC Global Inc. (BOOM, Financial) to release Q2 2025 earnings on August 5, 2025.\n\nConference call scheduled for 5:00 PM Eastern Time.\n\nWebcast replay available ...",
"url": "https://www.gurufocus.com/news/2993237/dmc-global-schedules-second-quarter-earnings-release-and-conference-call-boom-stock-news",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-07-22T13:19:24.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "BOOM",
"name": "DMC Global Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Energy",
"match_score": 82.26488,
"sentiment_score": 0.091067,
"highlights": [
{
"highlight": "<em>DMC</em> <em>Global</em> <em>Inc</em[+224 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>DMC</em> <em>Global</em> operates se[+271 characters]",
"sentiment": 0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "<em>DMC</em> <em>Global</em> Schedules Second Quarter Earnings Release and Conference Call | BOOM Stock News",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "b62311a1-7ee2-48a2-b7a9-efd5088aca59",
"title": "BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET",
"description": "PALO ALTO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ('BridgeBio” or the 'Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will release its second quarter financial results and business updates after the market closes on Tuesday, August 5, 2025. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day.",
"keywords": "BridgeBio, to, Host, Second, Quarter, 2025, Financial, Results, Conference, Call, on, Tuesday, , August, 5, , 2025, at, 4:30, pm, ET",
"snippet": "PALO ALTO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\"BridgeBio” or the \"Company”), a new type of biopharmaceutical c...",
"url": "https://www.manilatimes.net/2025/07/22/tmt-newswire/globenewswire/bridgebio-to-host-second-quarter-2025-financial-results-conference-call-on-tuesday-august-5-2025-at-430-pm-et/2153757",
"image_url": "https://www.manilatimes.net/manilatimes/uploads/images/2025/07/22/686488.png",
"language": "en",
"published_at": "2025-07-22T11:45:57.000000Z",
"source": "manilatimes.net",
"relevance_score": null,
"entities": [
{
"symbol": "BBIO",
"name": "BridgeBio Pharma, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 88.81884,
"sentiment_score": 0.35,
"highlights": [
{
"highlight": "., July 22, 2025 (GLOBE NEWSWIRE) -- <em[+331 characters]",
"sentiment": 0.3818,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>BridgeBio</em> <em>Pharma</em>[+347 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "bb47c34c-d3e9-4523-8aa2-9ffd9aea8546",
"title": "Henry Schein to Webcast Second Quarter 2025 Conference Call on Tuesday, August 5, 2025, at 8:00 a.m. ET | HSIC Stock News",
"description": "Henry Schein, Inc. (HSIC) to release Q2 2025 financial results on August 5, 2025. Earnings webcast scheduled at 8:00 a.m. Eastern Time with CEO Stanley",
"keywords": "GuruFocus, Article, News, GuruFocus News, HSIC",
"snippet": "Henry Schein, Inc. (HSIC, Financial) to release Q2 2025 financial results on August 5, 2025.\n\nEarnings webcast scheduled at 8:00 a.m. Eastern Time with CEO Stan...",
"url": "https://www.gurufocus.com/news/2992473/henry-schein-to-webcast-second-quarter-2025-conference-call-on-tuesday-august-5-2025-at-800-am-et-hsic-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C00000B9M.png?20",
"language": "en",
"published_at": "2025-07-22T11:45:17.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "0L3C.L",
"name": "Henry Schein, Inc.",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 73.631874,
"sentiment_score": 0.29266,
"highlights": [
{
"highlight": "<em>Henry</em> <em>Schein</em>, <em>Inc<[+327 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "South, Senior Vice President and CFO of [+243 characters]",
"sentiment": 0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Henry</em> <em>Schein</em> operates [+319 characters]",
"sentiment": 0.8591,
"highlighted_in": "main_text"
},
{
"highlight": "Recognized as a FORTUNE 500 Company and [+256 characters]",
"sentiment": 0.2023,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Henry</em> <em>Schein</em> to Webcast Second Quarter 2025 Conference Call on Tuesday, August 5, 2025, at 8:00 a.m. ET | HSIC Stock News",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "HSIC",
"name": "Henry Schein, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 73.6302,
"sentiment_score": 0.29266,
"highlights": [
{
"highlight": "<em>Henry</em> <em>Schein</em>, <em>Inc<[+327 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "South, Senior Vice President and CFO of [+243 characters]",
"sentiment": 0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Henry</em> <em>Schein</em> operates [+319 characters]",
"sentiment": 0.8591,
"highlighted_in": "main_text"
},
{
"highlight": "Recognized as a FORTUNE 500 Company and [+256 characters]",
"sentiment": 0.2023,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Henry</em> <em>Schein</em> to Webcast Second Quarter 2025 Conference Call on Tuesday, August 5, 2025, at 8:00 a.m. ET | HSIC Stock News",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "H1SI34.SA",
"name": "Henry Schein, Inc.",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 73.61473,
"sentiment_score": 0.29266,
"highlights": [
{
"highlight": "<em>Henry</em> <em>Schein</em>, <em>Inc<[+327 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "South, Senior Vice President and CFO of [+243 characters]",
"sentiment": 0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Henry</em> <em>Schein</em> operates [+319 characters]",
"sentiment": 0.8591,
"highlighted_in": "main_text"
},
{
"highlight": "Recognized as a FORTUNE 500 Company and [+256 characters]",
"sentiment": 0.2023,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Henry</em> <em>Schein</em> to Webcast Second Quarter 2025 Conference Call on Tuesday, August 5, 2025, at 8:00 a.m. ET | HSIC Stock News",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
}
]
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "us",
"total_documents": 3880,
"sentiment_avg": 0.283970872342349
}
]
}
Other details
Entity count
- 32,649